The radiotheranostics market size has grown rapidly in recent years. It will grow from $10.05 billion in 2025 to $11.43 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to increasing use of nuclear medicine diagnostics, expansion of oncology-focused clinical research, availability of therapeutic radioisotopes, rising adoption of PET and SPECT imaging, growing collaboration between pharma and imaging providers.
The radiotheranostics market size is expected to see rapid growth in the next few years. It will grow to $19.24 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to increasing approvals of radiotheranostic drugs, rising investments in precision oncology, expansion of isotope production infrastructure, growing demand for personalized cancer care, increasing integration of ai in treatment selection. Major trends in the forecast period include increasing adoption of targeted radioligand therapies, rising use of paired diagnostic and therapeutic isotopes, growing integration of precision imaging and therapy, expansion of personalized oncology applications, enhanced focus on molecular-level cancer targeting.
The rising prevalence of cancer is expected to drive the growth of the radiotheranostics market in the coming years. Cancer is a disease in which abnormal cells grow uncontrollably and spread to other parts of the body. Radiotheranostics therapies are widely used in oncology to deliver a highly personalized treatment approach by combining diagnostic and therapeutic radionuclide probes for the selective and targeted identification and treatment of specific cells, typically cancerous cells. These approaches are tailored to a patient’s underlying condition, improving treatment effectiveness and clinical outcomes. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases rose to 2,001,140 from 1,958,310 in 2023, representing an increase of 2.19%. Therefore, the growing prevalence of cancer is driving the radiotheranostics market.
Major companies operating in the radiotheranostics market are concentrating on developing innovative products to improve the production and availability of therapeutic radioisotopes, enhance treatment accuracy, and address the increasing demand for targeted cancer therapies. For instance, in May 2023, Advanced Cyclotron Systems Inc., a Canada-based supplier and service provider of cyclotrons primarily used for producing medical isotopes, launched TR-ALPHA, a dedicated cyclotron designed for the production of alpha-emitting radioisotopes for cancer treatment. The TR-ALPHA was developed to meet the market demand for a cost-effective cyclotron capable of generating large volumes of Astatine-211, one of the most promising alpha-emitting radioisotopes. It is smaller, more affordable, and easier to operate than earlier models, making it well suited for hospitals, research institutions, and organizations seeking efficient production of therapeutic alpha-emitting radioisotopes.
In June 2023, Ariceum Therapeutics GmbH, a Germany-based radiopharmaceutical company, acquired Theragnostics Ltd. for $41.5 million. Through this acquisition, Ariceum aims to expand its portfolio of therapeutic and diagnostic assets in late preclinical and early clinical development and to extend its presence in the United States. Theragnostics Ltd. is a US-based radiopharmaceutical company specializing in radio-theranostics.
Major companies operating in the radiotheranostics market are Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc, Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.
North America was the largest region in the radiotheranostics market in 2025. The regions covered in the radiotheranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radiotheranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the radiotheranostics market by increasing costs of imported radioisotopes, imaging equipment, radiopharmaceutical production systems, and precision diagnostic devices. Pharmaceutical companies and hospitals in North America and Europe are most affected due to reliance on cross-border isotope supply chains, while Asia-Pacific faces higher costs for research and clinical deployment. These tariffs are raising treatment and development costs and slowing market expansion. At the same time, they are driving investments in domestic isotope production, regional supply chain development, and localized radiopharmaceutical manufacturing capabilities.
The radiotheranostics market research report is one of a series of new reports that provides radiotheranostics market statistics, including radiotheranostics industry global market size, regional shares, competitors with a radiotheranostics market share, detailed radiotheranostics market segments, market trends and opportunities, and any further data you may need to thrive in the radiotheranostics industry. This radiotheranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Radiotheranostics refers to diagnostic and therapeutic approaches that use imaging techniques combined with radioactive substances to identify specific targets within the body. It is used to deliver targeted radiation therapy to precise locations, enabling personalized cancer treatment while reducing damage to healthy tissues, thereby improving treatment outcomes and patient care.
The primary radioisotopes used in radiotheranostics include technetium-99, gallium-68, iodine-131, iodine-123, fludeoxyglucose-18F, yttrium-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. Technetium (Tc) is a silver-gray radioactive metal that occurs naturally in extremely small amounts in the earth’s crust but is predominantly produced artificially and is used for scanning the skeleton and heart muscle. It is also employed to image the brain, thyroid, lungs, liver, spleen, kidneys, gall bladder, bone marrow, salivary and lacrimal glands, as well as in certain specialized medical research. The different approaches include targeted therapeutics and targeted diagnostics, which are applied in both oncology and non-oncology settings. The end users include hospitals and clinics, pharmaceutical and biotechnology companies, and others.
The radiotheranostics market consists of sales of iodine-125, radium-223 (223Ra), astatin-211 (211At), actinium-225 (225Ac), lead-212 (212Pb), bismuth-212 (212Bi), thorium-227, strontium-89 (89Sr), rhenium-188 (188Re), and samarium-153 (153Sm). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The radiotheranostics market size is expected to see rapid growth in the next few years. It will grow to $19.24 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to increasing approvals of radiotheranostic drugs, rising investments in precision oncology, expansion of isotope production infrastructure, growing demand for personalized cancer care, increasing integration of ai in treatment selection. Major trends in the forecast period include increasing adoption of targeted radioligand therapies, rising use of paired diagnostic and therapeutic isotopes, growing integration of precision imaging and therapy, expansion of personalized oncology applications, enhanced focus on molecular-level cancer targeting.
The rising prevalence of cancer is expected to drive the growth of the radiotheranostics market in the coming years. Cancer is a disease in which abnormal cells grow uncontrollably and spread to other parts of the body. Radiotheranostics therapies are widely used in oncology to deliver a highly personalized treatment approach by combining diagnostic and therapeutic radionuclide probes for the selective and targeted identification and treatment of specific cells, typically cancerous cells. These approaches are tailored to a patient’s underlying condition, improving treatment effectiveness and clinical outcomes. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases rose to 2,001,140 from 1,958,310 in 2023, representing an increase of 2.19%. Therefore, the growing prevalence of cancer is driving the radiotheranostics market.
Major companies operating in the radiotheranostics market are concentrating on developing innovative products to improve the production and availability of therapeutic radioisotopes, enhance treatment accuracy, and address the increasing demand for targeted cancer therapies. For instance, in May 2023, Advanced Cyclotron Systems Inc., a Canada-based supplier and service provider of cyclotrons primarily used for producing medical isotopes, launched TR-ALPHA, a dedicated cyclotron designed for the production of alpha-emitting radioisotopes for cancer treatment. The TR-ALPHA was developed to meet the market demand for a cost-effective cyclotron capable of generating large volumes of Astatine-211, one of the most promising alpha-emitting radioisotopes. It is smaller, more affordable, and easier to operate than earlier models, making it well suited for hospitals, research institutions, and organizations seeking efficient production of therapeutic alpha-emitting radioisotopes.
In June 2023, Ariceum Therapeutics GmbH, a Germany-based radiopharmaceutical company, acquired Theragnostics Ltd. for $41.5 million. Through this acquisition, Ariceum aims to expand its portfolio of therapeutic and diagnostic assets in late preclinical and early clinical development and to extend its presence in the United States. Theragnostics Ltd. is a US-based radiopharmaceutical company specializing in radio-theranostics.
Major companies operating in the radiotheranostics market are Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc, Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.
North America was the largest region in the radiotheranostics market in 2025. The regions covered in the radiotheranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radiotheranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the radiotheranostics market by increasing costs of imported radioisotopes, imaging equipment, radiopharmaceutical production systems, and precision diagnostic devices. Pharmaceutical companies and hospitals in North America and Europe are most affected due to reliance on cross-border isotope supply chains, while Asia-Pacific faces higher costs for research and clinical deployment. These tariffs are raising treatment and development costs and slowing market expansion. At the same time, they are driving investments in domestic isotope production, regional supply chain development, and localized radiopharmaceutical manufacturing capabilities.
The radiotheranostics market research report is one of a series of new reports that provides radiotheranostics market statistics, including radiotheranostics industry global market size, regional shares, competitors with a radiotheranostics market share, detailed radiotheranostics market segments, market trends and opportunities, and any further data you may need to thrive in the radiotheranostics industry. This radiotheranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Radiotheranostics refers to diagnostic and therapeutic approaches that use imaging techniques combined with radioactive substances to identify specific targets within the body. It is used to deliver targeted radiation therapy to precise locations, enabling personalized cancer treatment while reducing damage to healthy tissues, thereby improving treatment outcomes and patient care.
The primary radioisotopes used in radiotheranostics include technetium-99, gallium-68, iodine-131, iodine-123, fludeoxyglucose-18F, yttrium-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. Technetium (Tc) is a silver-gray radioactive metal that occurs naturally in extremely small amounts in the earth’s crust but is predominantly produced artificially and is used for scanning the skeleton and heart muscle. It is also employed to image the brain, thyroid, lungs, liver, spleen, kidneys, gall bladder, bone marrow, salivary and lacrimal glands, as well as in certain specialized medical research. The different approaches include targeted therapeutics and targeted diagnostics, which are applied in both oncology and non-oncology settings. The end users include hospitals and clinics, pharmaceutical and biotechnology companies, and others.
The radiotheranostics market consists of sales of iodine-125, radium-223 (223Ra), astatin-211 (211At), actinium-225 (225Ac), lead-212 (212Pb), bismuth-212 (212Bi), thorium-227, strontium-89 (89Sr), rhenium-188 (188Re), and samarium-153 (153Sm). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Radiotheranostics Market Characteristics
3. Radiotheranostics Market Supply Chain Analysis
4. Global Radiotheranostics Market Trends and Strategies
5. Radiotheranostics Market Analysis of End Use Industries
7. Global Radiotheranostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Radiotheranostics Total Addressable Market (TAM) Analysis for the Market
9. Radiotheranostics Market Segmentation
10. Radiotheranostics Market Regional and Country Analysis
11. Asia-Pacific Radiotheranostics Market
12. China Radiotheranostics Market
13. India Radiotheranostics Market
14. Japan Radiotheranostics Market
15. Australia Radiotheranostics Market
16. Indonesia Radiotheranostics Market
17. South Korea Radiotheranostics Market
18. Taiwan Radiotheranostics Market
19. South East Asia Radiotheranostics Market
20. Western Europe Radiotheranostics Market
21. UK Radiotheranostics Market
22. Germany Radiotheranostics Market
23. France Radiotheranostics Market
24. Italy Radiotheranostics Market
25. Spain Radiotheranostics Market
26. Eastern Europe Radiotheranostics Market
27. Russia Radiotheranostics Market
28. North America Radiotheranostics Market
29. USA Radiotheranostics Market
30. Canada Radiotheranostics Market
31. South America Radiotheranostics Market
32. Brazil Radiotheranostics Market
33. Middle East Radiotheranostics Market
34. Africa Radiotheranostics Market
36. Radiotheranostics Market Competitive Landscape and Company Profiles
37. Radiotheranostics Market Other Major and Innovative Companies
40. Radiotheranostics Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Radiotheranostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses radiotheranostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for radiotheranostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radiotheranostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Radioisotope: Technetium-99; Gallium-68; Iodine-131; Iodine-123; Fludeoxyglucose-18F; Yttrium-90; Lutetium (Lu) 177; Copper (Cu) 67; Copper (Cu) 64; Other Radioisotopes2) By Approach: Targeted Therapeutic; Targeted Diagnostic
3) By Application: Oncology; Non-Oncology
4) By End-Users: Hospitals And Clinics; Pharmaceutical And Biotechnology Companies; Other End-Users
Subsegments:
1) By Technetium-99: Technetium-99m; Technetium-99 Pertechnetate2) By Gallium-68: Gallium-68 DOTATATE; Gallium-68 PSMA
3) By Iodine-131: Iodine-131 For Thyroid Cancer Treatment; Iodine-131 For Hyperthyroidism Treatment
4) By Iodine-123: Iodine-123 For Thyroid Scans; Iodine-123 For Cardiac Imaging
5) By Fludeoxyglucose-18F (FDG): FDG For Oncology Imaging; FDG For Brain Imaging
6) By Yttrium-90: Yttrium-90 Microspheres For Liver Cancer; Yttrium-90 For Radioimmunotherapy
7) By Lutetium (Lu) 177: Lutetium-177 PSMA For Prostate Cancer; Lutetium-177 DOTATATE For Neuroendocrine Tumors
8) By Copper (Cu) 67: Copper-67 For Targeted Radiotherapy; Copper-67 In Clinical Trials
9) By Copper (Cu) 64: Copper-64 For PET Imaging; Copper-64 For Radiotherapy
10) By Other Radioisotopes: Radium-223; Samarium-153; Other Emerging Radioisotopes In Theranostics
Companies Mentioned: Lantheus Holdings Inc.; Cardinal Health Inc.; GE Healthcare Inc.; Bayer AG; Novartis AG; Siemens Healthineers; Orano Med; Curium SAS; IBA Molecular; The Eckert & Ziegler Group; Advanced Accelerator Applications (AAA); Telix Pharmaceuticals Limited.; Abdera Therapeutics; Blue Earth Diagnostics; Sirtex Medical Limited; Y-mAbs Therapeutics Inc.; ITM Radiopharma; NorthStar Medical Radioisotopes LLC; Trasis S.A.; Molecular Targeting Technologies Inc.; RadioMedix Inc; Clarity Pharmaceuticals; Actinium Pharmaceuticals Inc.; Navidea Biopharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Radiotheranostics market report include:- Lantheus Holdings Inc.
- Cardinal Health Inc.
- GE Healthcare Inc.
- Bayer AG
- Novartis AG
- Siemens Healthineers
- Orano Med
- Curium SAS
- IBA Molecular
- The Eckert & Ziegler Group
- Advanced Accelerator Applications (AAA)
- Telix Pharmaceuticals Limited.
- Abdera Therapeutics
- Blue Earth Diagnostics
- Sirtex Medical Limited
- Y-mAbs Therapeutics Inc.
- ITM Radiopharma
- NorthStar Medical Radioisotopes LLC
- Trasis S.A.
- Molecular Targeting Technologies Inc.
- RadioMedix Inc
- Clarity Pharmaceuticals
- Actinium Pharmaceuticals Inc.
- Navidea Biopharmaceuticals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 11.43 Billion |
| Forecasted Market Value ( USD | $ 19.24 Billion |
| Compound Annual Growth Rate | 13.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
